INTRODUCTION
Prostate cancer is one of the most common malignancies and causes of death among men in western societies. It has thus attracted the interest of the scientific community, which has resulted in great improvements in survival rates in recent years. As early as the 1940s, Huggins and Hodges first demonstrated that prostate cancer is androgen dependent, 1 initiating the wide use of androgen deprivation as an adjuvant therapy. Similarly, during the late 70's the clinical significance of the prostate specific antigen (PSA) was shown, resulting in early disease detection and monitoring of its evolution. Despite these significant achievements, a major persistent therapeutic challenge remains in prostate cancer: the discovery of new treatment strategies for the disease when hormone resistance sooner or later develops (castration resistant prostate cancer, CRPC). This presupposes a better understanding of the mechanisms involved in androgens actions in prostate cancer. In the following sections we will present an overview of our knowledge accumulated to date on the role of androgen receptor in prostate cancer. Its different modes of action and their therapeutic value will be analyzed.
ANDROGEN RECEPTOR STRUCTURE, CELLULAR LOCALIZATION AND FUNCTION
Androgen receptor (AR) is a 919 amino acid protein with a mass of 110kDa and, as a member of the nuclear receptor superfamily, it contains four distinct domains 2 ( Figure 1 ): an N-terminal domain (NTD, aa 1-537), a highly conserved DNA binding domain (DBD, aa 538-625), a hinge region (aa 626-669) and a ligand binding domain (LBD, aa 670-919). The short hinge region contains one of the four signals for the nuclear transport of AR (nuclear localization signal, NLS) which is important for AR-mediated transcriptional biological responses. The other three NLSs reside in the ligand binding domain, the DNA binding domain and the N-terminal domain. 3 The latter can activate transcription independently of ligand binding and contains transcriptional activation functions (AF) -1 and -5. A third transcriptional activation function, AF-2, is located in the ligand binding domain. All AFs can interact with LxxLL-containing co-regulators, even though AF-2 has a low affinity. 4 Interestingly, the AF-2 of AR, in contrast to other nuclear receptors, primarily interacts with coactivators that contain FxxLF motifs. These motifs are also present in the NTD of the receptor and therefore NTD and co-regulatory proteins compete for AF-2 binding. The importance of this competition is unknown. 4, 5 Another motif at the NTD that is involved in the NTD and LBD interaction is 23FQNLF27 at position 23. 6, 7 This interaction is very strong, so that any deletion or mutation that involves this motif abrogates NTD-LBD interaction. 7 AR can exist in a number of variants ( Figure 1 ). The first that was described is AR45 which lacks the entire NTD encoded by exon 1; it contains instead a seven amino acid N-terminal extension 8 and has a molecular weight of 45kDa. AR45 has an inhibitory effect on AR function and its presence inhibits the proliferation of the hormone-sensitive LNCaP human prostate cancer cells. 8 Moreover , variants with  changes at the carboxyl end of the protein have been  found, such as a number of truncated AR proteins  (ARV567ES, ARV1, ARV7) 9,10,12 with intact NTD and DBD but a short variant-specific peptide replacing the functional LBD. In contrast to AR45, ARV567ES functions as a constitutively active receptor, increases AR expression and enhances its transcriptional activity. Both ARV7 and ARV567ES enhance cell survival in an androgen depleted environment and are up-regulated in CRPC. [10] [11] [12] Another splice variant is AR23 that has an insertion of 23 amino acids at the DNA binding domain, which exhibit only cytoplasmic activity altering the activity of transcription 13 Finally, another splice variant, AR8, has recently been demonstrated, which lacks the DBD additionally to the NTD and is primarily localized at the plasma membrane. 14 This variant has been shown to cooperate with classical AR and EGFR by increasing AR tyrosine phospho- rylation, leading to enhanced androgen and growth factor response in prostate cancer cells.
14 All these variants have been implicated in androgen-insensitive prostate cancer cell growth, which will be discussed in detail below.
AR primarily resides in the cytoplasm as a dimmer and a complex with heat shock (such as HSP-90) and other chaperone proteins, which are tethered to cytoskeletal proteins, such as filamin A that interacts directly with AR and facilitates AR translocation to the nucleus. 20 Upon androgen binding, the complex is disrupted and the liganded AR as a dimmer becomes phosphorylated, along with several co-regulators, and enters the nucleus where it interacts with the DNA at certain androgen response elements (AREs) affecting the transcription of a number of genes, such as PSA.
21,22
The DBD domains of the receptor dimmer recognize hexameric binding sites (organized in inverted repeats) separated by three nucleotides. The classical consensus sequence for ARE is 5'-TGTTCT-3' and is also the same for glucocorticoid, mineralocorticoid and progestagen receptors. 23, 24 However, for AR there are also selective AREs which seem to be partial direct repeats of the above motif and to bind the DBD of AR but not that of the glucocorticoid receptor. 25 Additionally, AR can be trans-activated by growth factors (i.e. EGF, IGF, KGF) and cytokine (i.e. IL6) signaling. Indeed, AR has been described as the target of several MAPKs such as Akt/PKB, PKA, PKC (Figure 2 ). This cross-talk of AR with growth factor signaling events is extensively studied since it has been associated with metastatic and hormone resistant disease state (see below and Reference 26 for a review).
Finally, during the last decade membrane initiated androgen actions have been described in several cell AR antagonists like cyproterone acetate or flutamide do not inhibit these actions, 37 which d) have also been observed in cells (DU-145) 37 showing an androgen independent growth due to absence or, as recently demonstrated, expression of low levels of classical AR. 44 Therefore, (a) new receptor element(s) that binds androgens is(are) present at the membrane and/or it is an AR isoform(s) that has previously been described as existing in prostate cancer cells as the result of an alternative splicing (see above).
ANDROGEN RECEPTOR AS A TARGET IN PROSTATE CANCER THERAPY
In prostate cancer, luminal cells that constitute the great majority of cells depend for their survival on androgens, whose actions are primarily mediated through AR. Consequently, these cells express high levels of AR, in contrast to the more undifferentiated basal layer cells that are androgen independent and express low levels of AR. In fact, AR in basal epithelial cells has been shown to play a suppressive role in their proliferation. 45 Stromal cells also express AR but at lower levels in areas surrounding cancerous tissue. In contrast to epithelial cells, the role of stromal AR in prostate carcinogenesis is controversial. It has been shown that AR expressing stromal cells suppressed prostate cancer growth in vitro and in vivo, suggesting an opposite role for AR in the stromal layer which can influence prostate cancer cell growth. 46 On the other hand, two recent studies demonstrated that loss of stromal AR leads to suppressed prostate carcinogenesis by suppressing epithelial growth and tumor-promoting environment by modulating proinflammatory cytokines. 47, 48 However, the extensively studied androgen dependence of prostate epithelial cancer cells remains the basis for the widely used hormonal therapies.
The better understanding of androgen synthesis and mode of action led to the development of a number of androgen suppression approaches, 49 which are widely utilized for advanced/metastatic prostate cancer, as recommended by the guidelines of the European Association of Urology. 50 Moreover, they are also used in earlier stages of prostate cancer alone, or most often as neo-adjuvant/adjuvant therapy after radical prostatectomy and/or radiotherapy. 51 These therapies include three major categories: (i) surgical orchiectomy, estrogens, LHRH agonists or antagonists that reduce serum testosterone levels, the most active intracellular androgen, DHT and (iii) anti-androgens that block the action of androgens with AR being target. The most widely used anti-androgens are the non-steroidals bicalutamide, flutamide and nilutamide and the steroidal cyproterone acetate, which compete with androgens for AR binding and therefore inhibit their action as well as reducing their expression. Non-steroidal anti-androgens have the advantage of not having any steroidal side effect.
When applied, androgen deprivation initially induces apoptosis of prostate cancer cells, resulting in a significant tumor regression. However, the majority of tumors become resistant at a later stage 52 and patients develop a hormone refractory disease, also known as CRPC. Several mechanisms have been described so far for this disease progression characterized by tumor cell survival in an androgen-depleted environment. These include: a) Altered expression of steroidogenesis enzymes by cancer cells, leading to increased androgen levels within the tumor environment. 53 Increased expression of enzymes such as CYP19A1, SRD5A2, HSD3B2, HSD17B3, AKR1C3, UGT2B15, in combination with the loss of enzymes mediating DHT catabolism, such as AKR1C1, AKR1C2, contributing to cancer cell survival in an androgen deprived environment. 54, 55 b) Overexpression of AR due to DNA amplification and response to low levels of androgens. 56 More than 60% of CRPC metastasis has been found to overexpress AR 57, 58 and approximately in one third of these cases the mechanism of this overexpression is the amplification of the AR locus. 57, 59 Other mechanisms may include increased transcription (increased AR expression has been described due to E2F activity in retinoblastoma deficient tumors 60 ) and/or increased mRNA stability.
c) AR gene mutations that result in altered ligand specificity and account for only 10% of the patients that progress to CRPC. 61, 62 AR mutations in the hinge region and LBD are responsible for increased affinity to DHT, mutations at the N-terminal of the LBD broaden AR specificity for other ligands such as glucocorticoids and progesterone and mutations within the AF-2 region convert antagonists to antagonists. 63, 64 d) Activation of signaling pathways that can induce AR activity (Figure 2 ) even independently of the presence of androgens. 65 Several signaling pathways have been described as enhancing AR activity, indirectly via the phosphorylation of several transcription factors or directly by phosphorylating AR itself. This activation can enhance AR activity, at very low levels or in the absence of androgens, following androgen deprivation therapy. The pathways implicated so far are that of EGF, IGF, IL6, Wnt and the Ras-Raf-MAP kinase pathway. [65] [66] [67] [68] [69] EGF treatment of LNCaP cells in the absence of androgens induces AR phosphorylation (tyr-267,-534). 70 Interestingly, wnt3A protein and beta catenin can recruit AR to the promoter regions of several genes (such as myc, cyclin D1 and PSA). 67 Additionally, activation of Cdk1, PKA, PI3K/ Akt and Stat3 may enhance AR transcriptional responses.
26 Cdk1 phosphorylates AR at serine 81 and stabilizes the receptor, 71 activation of the PI3K/Akt pathway results in AR phosphorylation and promotion of cell survival 72 and Stat3 can form a heterologous complex with AR (stat3-AR) by interacting directly with amino acids 234-558 in the NTD of AR. 73 Therefore, whenever stat3 is activated, for example as a response to EGF and IL6, then AR is activated. Table  1 for details). g) Presence of undifferentiated AR negative cancer stem cells that can survive in an androgen-depleted environment. 76 Cancer stem cell theory states that prostate stem cells that are present within the tumor can differentiate to transient amplifying cells which give rise to committed basal and later differentiate to luminal cells. Interestingly, in the majority of cancer stem cell phenotypes (no consensus phenotype has yet been achieved) ARs are undetectable; cells are therefore not dependent on androgen for survival and thus may escape androgen deprivation apoptosis, 76 leading to the progression of the disease.
All these mechanisms suggest that an important distinction should be made between serum androgen levels and androgenic action at the cellular level and point to the need for the development of markers reflecting the presence of active androgens at the tissue level. 77 When CRPC has developed, the available therapeutic choices are rather few and survival is limited to 9-13 months for metastatic CRPC. 78 Docetaxel chemotherapy has FDA approval since 2004, while during the last three years cabazitaxel (a semisynthetic taxane), sipuleucel-T (an immunotherapy against prostatic acid phosphatase), denosumab (monoclonal antibody against RANKL that prevents osteoclast mediated bone destruction) and abiraterone (an inhibitor of CYP17, involved in adrenal steroidosynthesis) have also been approved. 79 In spite of these advances, treatment of CRPC still comprises the major therapeutic challenge in prostate cancer.
Recently, a new and more potent AR antagonist, MDV3100, has been reported. 80, 81 It binds to AR with greater affinity and blocks AR translocation to the nucleus, co-activator and DNA binding and has no agonistic activity. It is at present in phase III trials for the treatment of late stage metastatic disease. In the category of small molecule antagonists for AR, there are three other agents undergoing evaluation in early clinical studies (phase I/II). The first is ARN-509 which has an in vitro activity similar to MDV3100 but which is enhanced in vivo. 80, 82 It impairs nuclear AR localization and DNA binding and it is a potent inhibitor of tumor growth with greater efficacy, thus reducing the seizure risk observed with high doses of MDV3100, via antagonism of the central nervous system (CNS)-based GABA A receptor. AZD3514 is a selective AR down-regulator. It binds to the LBD of AR, inhibits AR translocation to the nucleus and transcription, but also reduces AR protein levels, thus differentiating it from other AR antagonists such as bicalutamide and MDV3100. Thirdly, Galeterone (TOK-001) is a dual molecule that inhibits CYP17 but is also an AR antagonist and causes receptor down-regulation. It was found to inhibit hormone resistant prostate cancer cell lines that are no longer sensitive to bicalutamide and prostate cancer xenograft models. 83, 84 Additionally, two other classes of agents with anti-androgenic action are quite promising for the treatment of CRPC and their safety and efficacy is either under assessment or will be in the near future. They include compounds that interfere with the AR transcriptional complex and molecules that target AR but in a LBD independent manner. In the first class, an Hsp27-targeting locked antisense (OGX-427) is a possible candidate. Ligand activated AR phosphorylates Hsp27 which displaces Hsp90 from the complex with AR and enhances AR stability and transcriptional activity. Knocking down Hsp27 with OGX-427 results in increased AR degradation, AR transcriptional activity and increased apoptosis, as shown in LNCaP cells. 85 At the moment, OGX-427 is undergoing evaluation together with prednisone in a phase II trial. The second class contains molecules that can act as non-competitive inhibitors by targeting AR at a different site other than the LBD. This need arose through the fact that, as described above, AR can exist in several mutated shorter forms lacking part of or the entire LBD and exhibits constitutive activity. Therefore, for CRPC where AR mutants exist, NTD has been a possible target. 86 A representative compound of this class is a small molecule named EPI-001, identified by Andersen and colleagues by screening extracts from marine sponge that inhibits AR activity, regardless of the presence of a ligand. It interacts with AF-1 in NTD, inhibits N terminal and C terminal interaction and blocks protein-protein interaction with AR and AR interaction with AREs. As a consequence, it blocked androgen induced proliferation and tumor growth in CRPC xenografts. 87 Finally, it should be noted that due to the existence of a cross-talk of AR with growth factor signaling events, a second line hormonal treatment such as anti-survival factor treatment has been utilized with biochemical and/or clinical benefits in a large portion of CRPC patients. This includes the use of dexamethasone and/or somatostatin analogs along with androgen ablation and anti-androgen therapy. 88, 89 
POTENTIAL ROLE OF MEMBRANE INITIATED ANDROGEN ACTIONS IN ADVANCED PROSTATE CANCER THERAPY
Our knowledge on membrane initiated androgen actions in prostate cancer so far is very limited. However, the first evidence that we have from our work in the field during the last decade points to a significant role for membrane AR that should definitely be further exploited. In fact, we demonstrated that membrane ARs are more frequently expressed in cancer cells than in BPH or normal prostate cells. 35 Interestingly, we detected mAR in a number of cell lines that are characterized as androgen-insensitive 37 and, after developing a fluorescence detection method in paraffin embedded tissues, we reported that their expression increased with the Gleason score, pointing out that they are preferentially expressed in more undifferentiated disease. 36 Taking into consideration the pro-apoptotic effect of mAR activation, this finding is particularly important. Indeed, mAR presence at the more advanced stages of the disease, when cancer cells are unresponsive to androgen deprivation therapy, could be a novel therapeutic target, since their activation can lead to tumor regression.
In fact, over the last 70 years during which a connection between androgens and prostate cancer has been established, there have been studies demonstrating that patients with metastatic hormone refractory prostate cancer at a terminal stage showed great improvement after treatment with testosterone. This type of treatment with high doses of testosterone, known as testosterone replacement therapy (TRT), has also been utilized by some clinicians for hypogonadism after initial cancer therapy, including primary androgen-deprivation therapy (ADT). Symptoms of hypogonadism were improved but there is reluctance to administer this kind of therapy due to a possible risk of stimulating prostate cancer growth. However, as described by Leibowitz and colleagues, 40% of patients on TRT responded well and had no significant PSA increase or clinical/symptomatic disease progression. 90 In 2009, two phase I trials of exogenously administered high dose of testosterone in castration-resistant prostate cancer were published. 91, 92 Only in the second study, in which testosterone levels were raised to an average of 589 ng/dL in 7/12 recruited patients, was a significant decrease in PSA levels (7.9%-49%) ob-served. 92 However, it should be noted that the effect of high dose testosterone on PSA most likely cannot be attributed to a direct non-genomic action on PSA but to its extranuclear effect, which has been found to induce apoptotic death of prostate cancer cells. Finally, at the moment there is an ongoing phase II trial for exogenous testosterone plus Dutasteride (a of testosterone to its more active form DHT) for the treatment of castrate metastatic prostate cancer that will be completed in 2013. The difference between the two trials and the fact that some patients respond well to TRT while others do not indicates that new tools are required for the better selection of those patients that will respond to such a treatment.
So, how might androgen influence CRPC regression? A hypothesis advanced by our group in recent years is that this may occur through membrane androgen sites. Indeed, impermeable androgen (acting exclusively on these membrane sites), 37 as well as micromolecular agonists of membrane ARs (mARs), 93 induce regression of tumor xenografts, initiated by AR-negative prostate cancer cells, mimicking CRPC. In this respect, mAR presence may represent a possible marker for a positive TRT response as well as a new target for the development of specific therapeutic agonists. Furthermore, the presence of mAR in high grade tumors 36 and mesenchymal stem cells (unpublished observations) are candidates for such a potential role. Finally, we have recently tested prostate cancer specimens of a small number of patients who responded to TRT in comparison to non-responders for mAR expression (unpublished data). Interestingly, those patients who exhibited high levels of mAR (Figure 3) were those that responded well to TRT, with PSA below 0.2ng/ml. As expected, non-responders showed low or no expression of mAR.
CONCLUDING REMARKS
The continuous progress being made in the field of androgen action and prostate cancer has led to a number of therapeutic advances, lowering mortality rates and improving the quality of life of thousands of men worldwide. 94, 95 Since its identification, AR has been one of the main therapeutic targets and the use of anti-androgens is still the treatment choice for early and advanced disease. 96 AR is expressed in the great majority of prostate cancer cases, 97 while so far no correlation between its expression and Gleason score, node involvement, metastasis stage, pre-treatment PSA levels, prognosis or response to therapy has been established, even though different expression levels have been observed. 97 As a consequence, AR is not routinely assayed in prostate cancer biopsies, as is the standard practice for estrogen receptors in breast cancer. AR is still present even when the disease becomes unresponsive to standard hormone deprivation therapies and a more aggressive CRPC phenotype emerges. Possibly, (a) different mutated hyperactive form(s) may exist or emerge, trans-activated by growth factors, in an androgen independent manner and/or is/ are located in a different cell compartment, such as the plasma membrane, initiating specific signaling cascades. As our group has previously reported, mAR exhibits an inhibitory action on cell growth that could be exploited therapeutically. In addition, we must not forget that AR can also be found in the stromal compartment of the tumor where primary evidence (stromal AR is less studied) indicates that stromal AR is associated with cancer progression. 46 Therefore, more work is required in order to decipher the role of AR isoforms and/or membrane AR at the different stages of prostate cancer and within different cell populations other than the luminal cells, such as stromal and cancer stem cells. New molecules must be identified with longer duration and greater efficacy in CRPC that will differentially activate or antagonize specific isoforms. In parallel, it is essential to identify new biomarkers for therapy selection and prediction of patient's response. Novel membrane AR molecules and their agonists may represent such a target, as demonstrated above. 
